Personensuche
Personensuche
Es wurde 1 Person gefunden.
Aktuelle Veranstaltungen
-
2024 WS
Vergangene Veranstaltungen (max. 10)
-
2024 SS
-
2023 WS
-
2023 SS
-
2022 WS
-
2022 SS
-
2021 WS
Die folgenden Publikationen sind in der Online-Universitätsbibliographie der Universität Duisburg-Essen verzeichnet. Weitere Informationen finden Sie gegebenenfalls auch auf den persönlichen Webseiten der Person.
-
Gemtuzumab ozogamicin plus midostaurin in combination with standard ‘7 + 3’ induction therapy in newly diagnosed AML : Results from the SAL-MODULE phase I studyIn: British Journal of Haematology Jg. 204 (2024) Nr. 6, S. 2254 - 2258Online Volltext: dx.doi.org/ (Open Access)
-
Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALLIn: Journal of Clinical Oncology (JCO) Jg. 42 (2024) Nr. 3, S. 273 - 282Online Volltext: dx.doi.org/
-
Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligenceIn: npj Digital Medicine Jg. 7 (2024) Nr. 1, 76Online Volltext: dx.doi.org/ (Open Access)
-
Single or Double Induction With 7 + 3 Containing Standard or High-Dose Daunorubicin for Newly Diagnosed AML : The Randomized DaunoDouble Trial by the Study Alliance LeukemiaIn: Journal of Clinical Oncology (JCO) (2024) in pressOnline Volltext: dx.doi.org/
-
Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimensIn: Haematologica / The Hematology Journal Jg. 109 (2024) Nr. 8, S. 2469 - 2477Online Volltext: dx.doi.org/ (Open Access)
-
Alterations of cohesin complex genes in acute myeloid leukemia : Differential co-mutations, clinical presentation and impact on outcomeIn: Blood Cancer Journal Jg. 13 (2023) Nr. 1, 18Online Volltext: dx.doi.org/ (Open Access)
-
Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4In: Haematologica / The Hematology Journal Jg. 108 (2023) Nr. 1, S. 34 - 41Online Volltext: dx.doi.org/ (Open Access)
-
General condition and comorbidity of long-term survivors of adult acute lymphoblastic leukemiaIn: Haematologica / The Hematology Journal Jg. 108 (2023) Nr. 7, S. 1758 - 1767Online Volltext: dx.doi.org/ (Open Access)
-
Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy : A real-world registry experienceIn: British Journal of Cancer (BJC) Jg. 129 (2023) Nr. 7, S. 1126 - 1133Online Volltext: dx.doi.org/ (Open Access)
-
Intensified cytarabine dose during consolidation in adult AML patients under 65 years is not associated with survival benefit : Real-world data from the German SAL-AML registryIn: Journal of Cancer Research and Clinical Oncology Jg. 149 (2023) Nr. 8, S. 4611 - 4621Online Volltext: dx.doi.org/ (Open Access)
-
Mutated IKZF1 is an independent marker of adverse risk in acute myeloid leukemiaIn: Leukemia Jg. 37 (2023) Nr. 12, S. 2395 - 2403Online Volltext: dx.doi.org/ (Open Access)
-
Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learningIn: Haematologica / The Hematology Journal Jg. 108 (2023) Nr. 3, S. 690 - 704Online Volltext: dx.doi.org/ (Open Access)
-
Secondary-type mutations do not impact outcome in NPM1-mutated acute myeloid leukemia : Implications for the European leukemia net risk classificationIn: Leukemia Jg. 37 (2023) Nr. 11, S. 2282 - 2285Online Volltext: dx.doi.org/ (Open Access)
-
Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profilesIn: Communications Medicine Jg. 3 (2023) Nr. 1, 68Online Volltext: dx.doi.org/ (Open Access)
-
Impact of IDH1 and IDH2 mutational subgroups in AML patients after allogeneic stem cell transplantationIn: Journal of Hematology and Oncology Jg. 15 (2022) Nr. 1, 126Online Volltext: dx.doi.org/ (Open Access)
-
Molecular profiling and clinical implications of patients with acute myeloid leukemia and extramedullary manifestationsIn: Journal of Hematology and Oncology Jg. 15 (2022) Nr. 1, 60Online Volltext: dx.doi.org/ (Open Access)
-
Factor IX p.A37V mutation causes severe bleeding in a patient with phenprocoumon therapyIn: European Journal of Medical Research Jg. 26 (2021) Nr. 1, 63Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition : A Descriptive Observational Retrospective Multicenter AnalysisIn: Frontiers in Oncology Jg. 11 (2021) 765608Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Impact of PTPN11 mutations on clinical outcome analyzed in 1529 patients with acute myeloid leukemiaIn: Blood Advances Jg. 5 (2021) Nr. 17, S. 3279 - 3289Online Volltext: dx.doi.org/ (Open Access)
-
Rationale and design of the 2 by 2 factorial design GnG-trial : A randomized phase-III study to compare two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and to compare double-blinded intensive postremission therapy with or without glasdegib in older patients with newly diagnosed AMLIn: Trials Jg. 22 (2021) Nr. 1, 765Online Volltext: dx.doi.org/ (Open Access)
-
Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia : Long-term follow-up of the randomized controlled SORAML trialIn: Leukemia Jg. 35 (2021) Nr. 9, S. 2517 - 2525Online Volltext: dx.doi.org/ (Open Access)
-
Targeting CD38 in acute myeloid leukemia interferes with leukemia trafficking and induces phagocytosisIn: Scientific Reports Jg. 11 (2021) Nr. 1, 22062Online Volltext: dx.doi.org/ Online Volltext (Open Access)
-
Acute myeloid leukemia–induced remodeling of the human bone marrow niche predicts clinical outcomeIn: Blood Advances Jg. 4 (2020) Nr. 20, S. 5257 - 5268Online Volltext: dx.doi.org/ (Open Access)
-
Corrigendum to ‘Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial’ [Eur J Canc 124 (January 2020) 25–36] (European Journal of Cancer (2020) 124 (25–36), (S0959804919307555), (10.1016/j.ejca.2019.09.027))In: European Journal of Cancer (EJC) Jg. 136 (2020) S. 207 - 208Online Volltext: dx.doi.org/ (Open Access)
-
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma : Post-hoc analysis from the PETAL trialIn: European Journal of Cancer (EJC) Jg. 124 (2020) S. 25 - 36Online Volltext: dx.doi.org/
-
Etoposide combined with FLAG salvage therapy is effective in multiple relapsed / refractory acute myeloid leukemiaIn: Acta Haematologica Jg. 143 (2020) Nr. 5, S. 438 - 445Online Volltext: dx.doi.org/ (Open Access)
-
Inflammation-driven activation of JAK/STAT signaling reversibly accelerates acute myeloid leukemia in vitroIn: Blood Advances Jg. 4 (2020) Nr. 13, S. 3000 - 3010Online Volltext: dx.doi.org/ (Open Access)
-
Supporting data for positron emission tomography-based risk modelling using a fixed-instead of a relative thresholding method for total metabolic tumor volume determinationIn: Data in Brief Jg. 28 (2020) 104976Online Volltext: dx.doi.org/ (Open Access)
-
Immune signature drives leukemia escape and relapse after hematopoietic cell transplantationIn: Nature Medicine Jg. 25 (2019) Nr. 4, S. 603 - 611Online Volltext: dx.doi.org/ (Open Access)
-
Nestin⁺NG2⁺ Cells Form a Reserve Stem Cell Population in the Mouse ProstateIn: Stem Cell Reports Jg. 12 (2019) Nr. 6, S. 1201 - 1211Online Volltext: dx.doi.org/ (Open Access)
-
Functional abnormalities and changes in gene expression in fibroblasts and macrophages from the bone marrow of patients with acute myeloid leukemiaIn: International Journal of Hematology Jg. 102 (2015) Nr. 3, S. 278 - 288Online Volltext: dx.doi.org/
-
Acral ischemia as a presenting manifestation of essential thrombocythemiaIn: International Journal of Hematology Jg. 94 (2011) Nr. 3, S. 219 - 220Online Volltext: dx.doi.org/
-
Amyloid tumourIn: British Journal of Haematology Jg. 150 (2010) Nr. 4, S. 387Online Volltext: dx.doi.org/
-
Single vs double induction with "7+3" containing 60 vs 90 mg daunorubicin for newly diagnosed acute myeloid leukemia : results from the randomized controlled SAL-DaunoDouble trial
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 27Online Volltext: dx.doi.org/ (Open Access) -
Venetoclax Plus High-Dose Cytarabine and Mitoxantrone (HAM-Ven) As Salvage Treatment for Relapsed/Refractory AML : Updated Results of the Phase-I/II SAL Relax Trial
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood Jg. 142 (2023) Nr. Supplement 1, S. 160 - 162Online Volltext: dx.doi.org/ (Open Access) -
Venetoclax plus high-dose cytarabine and mitoxantrone as feasible and effective novel treatment for relapsed AML : results of the phase-I RELAX trial (SAL-AMLCG)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 26 - 27Online Volltext: dx.doi.org/ (Open Access) -
Impact of IDH1 and IDH2 mutational subgroups in acute myeloid leukemia patients after allogeneic hematopoietic cell transplantationIn: Bone Marrow Transplantation Jg. 57 (2022) Nr. Suppl. 1, S. 17
-
Inotuzumab Ozogamicin Induction followed by Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood Jg. 140 (2022) Nr. Supplement 1, S. 510 - 512Online Volltext: dx.doi.org/ (Open Access) -
Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients : Excellent Outcome of Standard Risk Thymic T-ALL
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood Jg. 140 (2022) Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 115 - 117Online Volltext: dx.doi.org/ (Open Access) -
Single Versus Double Induction with "7+3" Containing 60 Versus 90 Mg Daunorubicin for Newly Diagnosed AML : Results from the Randomized Controlled SAL Dauno-Double Trial
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans, LA, USA,In: Blood Jg. 140 (2022) Nr. Supplement 1, S. 523 - 525Online Volltext: dx.doi.org/ Online Volltext (Open Access) -
Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML : Results of the Phase-I SAL Relax Trial
64th ASH Annual Meeting and Exposition, 10-13 December 2022, New Orleans,In: Blood Jg. 140 (2022) Nr. Supplement 1: 64th ASH Annual Meeting Abstracts, S. 3327 - 3328Online Volltext: dx.doi.org/ (Open Access) -
Venetoclax and Hypomethylating Agents Followed by Allogeneic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia
64th Annual Meeting and Exposition of the American Society of Hematology ; December 10 - 13, 2022, New Orleans,In: Blood Jg. 140 (2022) Nr. Supplement 1: 64th Annual Meeting, S. 12943 - 12944Online Volltext: dx.doi.org/ (Open Access) -
Characteristics and Outcome of Patients with Acute Myeloid Leukemia and Trisomy 4
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 1307 - 1310Online Volltext: dx.doi.org/ (Open Access) -
Final Induction Therapy Results of an Open Label Phase II Study Using Inotuzumab Ozogamicin for Induction Therapy, Followed By a Conventional Chemotherapy Based Consolidation and Maintenance Therapy in Patients Aged 56 Years and Older with Acute B-Lymphoblastic Leukemia (INITIAL-1 trial)
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 2300 - 2302Online Volltext: dx.doi.org/ (Open Access) -
Impact of Body Mass Index on Patient Outcome in Acute Myeloid Leukemia Patients Receiving Intensive Induction Therapy : A Real-World Registry Experience
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 3370 - 3371Online Volltext: dx.doi.org/ (Open Access) -
Intensified Cytarabine Dose during Consolidation Therapy in AML Patients Under 65 Years Is Not Associated with Survival Benefit
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 1242 - 1243Online Volltext: dx.doi.org/ (Open Access) -
Prediction of Complete Remission and Survival in Acute Myeloid Leukemia Using Supervised Machine Learning
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 108 - 110Online Volltext: dx.doi.org/ (Open Access) -
Real-World Experience of CPX-351 As First-Line Treatment in 188 Patients with Acute Myeloid Leukemia
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 33 - 35Online Volltext: dx.doi.org/ (Open Access) -
Real-world experience of CPX-351 as first-line treatment for patients with acute myeloid leukemiaIn: Blood Cancer Journal Jg. 11 (2021) Nr. 10, 164Online Volltext: dx.doi.org/ (Open Access)
-
Venetoclax-Azacitidine As Salvage Therapy and Bridge to Allogeneic Cell Transplantation in Relapsed/Refractory AML Compared to Historical Data of the SAL Registry Study
63rd ASH Annual Meeting and Exposition, 11-14 December 2021, Atlanta,In: Blood Jg. 138 (2021) Nr. Supplement 1: 63rd ASH Annual Meeting Abstracts, S. 4418 - 4420Online Volltext: dx.doi.org/ (Open Access) -
Dynamic model for risk assessment in diffuse large B-cell lymphoma based on positron emission tomography scanning
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie, 11. - 14. Oktober 2019, Berlin, Germany,In: Oncology Research and Treatment Jg. 42 (2019) Nr. Supplement 4: Abstracts, S. 67Online Volltext: dx.doi.org/ (Open Access) -
Acute Myeloid Leukemia Induced Remodelling of the Human Bone Marrow Niche Predicts Clinical Outcome
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1, S. 3851 - 3851Online Volltext: dx.doi.org/ (Open Access) -
Inhibition of CD38 Shows Anti-Leukemic Activity in Acute Myeloid Leukemia
60th ASH Annual Meeting; December 1-4, 2018; San Diego, USA,In: Blood Jg. 132 (2018) Nr. Supplement 1: 60th ASH Annual Meeting Abstracts, S. 1456 - 1456Online Volltext: dx.doi.org/ (Open Access) -
Cryptochrome 1 (CRY1) promoter methylation is associated with good prognosis in B-cell chronic lymphocytic leukemia (CLL)
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Onkologie. Berlin, 1.–5. Oktober 2010,In: Onkologie Jg. 33 (2010) Nr. Suppl. 6, S. 240 - 241Online Volltext: dx.doi.org/ -
Mimicking Clinical Trials with Synthetic Acute Myeloid Leukemia Patients Using Generative Artificial Intelligence
65th ASH Annual Meeting, December 9-12, 2023, San Diego, CA, USA,In: Blood Jg. 142 (2023) Nr. Supplement 1, S. 2268 - 2270Online Volltext: dx.doi.org/ (Open Access) -
Real-world experience with hypomethylating agents and venetoclax as induction or salvage therapy followed by allogeneic stem cell transplantation in patients with acute myeloid leukemia
Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie ; 13. bis 16. Oktober 2023, Hamburg, Germany,In: Oncology Research and Treatment Jg. 46 (2023) Nr. Supplement 5: DGHO Abstracts, S. 193Online Volltext: dx.doi.org/ (Open Access) -
Venetoclax-Based Salvage Therapy Improves Outcome in Relapsed/Refractory AML Patients Eligible for Intensive Treatment : A Propensity Score Matching Analysis
64th Annual Meeting and Exposition of the American Society of Hematology, December 10 - 13, 2022, New Orleans,In: Blood Jg. 140 (2022) Nr. Supplement 1: 64th Annual Meeting, S. 3317 - 3319Online Volltext: dx.doi.org/ (Open Access)